References analysis of the Wikipedia article "Ketanseriini" in the Finnish version

doi.org

dx.doi.org

B Persson, J Heykants, T Hedner: Clinical pharmacokinetics of ketanserin. Clinical Pharmacokinetics, 1991, 20. vsk, nro 4, s. 263279. PubMed:2036747 doi:10.2165/00003088-199120040-00002 ISSN 0312-5963 Artikkelin verkkoversio.

JA Orsini et al: ”Chapter 19 - Integumentary system: wound healing, management, and reconstruction”, Equine emergencies: treatment and procedures, s. 261. (4. painos) Saunders, 2014. doi:10.1016/B978-1-4557-0892-5.00019-2 ISBN 9781455708925

RN Brogden, EM Sorkin: Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. Drugs, 1990, 40. vsk, nro 6, s. 903–949. PubMed:2079001 doi:10.2165/00003495-199040060-00010 ISSN 0012-6667 Artikkelin verkkoversio.

NAR Vellinga et al: Effects of ketanserin on microcirculatory alterations in septic shock: an open-label pilot study. Journal of Critical Care, 2015, 30. vsk, nro 6, s. 1156–1162. PubMed:26264259 doi:10.1016/j.jcrc.2015.07.004 ISSN 1557-8615 Artikkelin verkkoversio.

AA Williams et al: Reduced levels of serotonin 2A receptors underlie resistance of Egr3 -deficient mice to locomotor suppression by clozapine. Neuropsychopharmacology, 2012, 37. vsk, nro 10, s. 22852298. PubMed:22692564 doi:10.1038/npp.2012.81 ISSN 1740-634X Artikkelin verkkoversio.

M Israilova et al: Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes. Pharmacology, 2002, 65. vsk, nro 2, s. 69–73. PubMed:11937776 doi:10.1159/000056189 ISSN 0031-7012 Artikkelin verkkoversio.

F Holze et al: Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 2020. PubMed:33059356 doi:10.1038/s41386-020-00883-6 ISSN 1740-634X Artikkelin verkkoversio.

BB Quednow et al: Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology, 2012, 37. vsk, nro 3, s. 630–640. PubMed:21956447 doi:10.1038/npp.2011.228 ISSN 0893-133X Artikkelin verkkoversio.

M Valle et al: Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. European Neuropsychopharmacology, 2016, 26. vsk, nro 7, s. 1161–1175. PubMed:27039035 doi:10.1016/j.euroneuro.2016.03.012 ISSN 1873-7862 Artikkelin verkkoversio.

P Quatresooz et al: Healing effect of ketanserin on chronic leg ulcers in patients with diabetes. Journal of the European Academy of Dermatology and Venereology, 2006, 20. vsk, nro 3, s. 277281. doi:10.1111/j.1468-3083.2006.01422.x ISSN 0926-9959 Artikkelin verkkoversio.

J Pope et al: Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. The Cochrane Database of Systematic Reviews, 1998, nro 2. PubMed:10796396 doi:10.1002/14651858.CD000954 ISSN 1469-493X Artikkelin verkkoversio.

nih.gov

pubmed.ncbi.nlm.nih.gov

Clinical pharmacokinetics of ketanserin pubmed.ncbi.nlm.nih.gov. Viitattu 15.12.2024. (englanniksi)

JM Nueten et al: Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. The Journal of Pharmacology and Experimental Therapeutics, 1981, 218. vsk, nro 1, s. 217–230. PubMed:6113280 ISSN 0022-3565 Artikkelin verkkoversio.

ncbi.nlm.nih.gov

sciencedirect.com

springer.com

link.springer.com

worldcat.org

Ketanseriini (Finnish Wikipedia)

aspetjournals.org

jpet.aspetjournals.org

clinicaltrials.gov

doi.org

dx.doi.org

drugs.com

fimea.fi

spc.fimea.fi

karger.com

nature.com

ncats.io

drugs.ncats.io